Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages

Oncotarget

Volumn 7, Issue 18, 2016, Pages 25683-25697

  Teng, Yun ^b   Mu, Jingyao ^b   Hu, Xin ^d,e   Samykutty, Abhilash ^b   Zhuang, Xiaoying ^b   Deng, Zhongbin ^b   Zhang, Lifeng ^b   Cao, Pengxiao ^b   Yan, Jun ^b   Miller, Donald ^b   Zhang, Huang Ge ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c University of Louisville School of Medicine   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Grapefruit derived nanovector; IRF2; Liver metastasis of colon cancer; M1 Kupffer cells; MiR 18a

Indexed keywords

ANTIMETASTATIC AGENT; B7 ANTIGEN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN 12; MICRORNA 18A; NANOCARRIER; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; LIPID; MICRORNA; NANOPARTICLE; PLANT EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; GRAPEFRUIT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LYMPHOCYTE ACTIVATION; MACROPHAGE; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; SURVIVAL TIME; UPREGULATION; ZETA POTENTIAL; ANIMAL; COLON TUMOR; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; IMMUNOLOGY; LIVER TUMOR; MACROPHAGE ACTIVATION; PATHOLOGY; PROCEDURES; SECONDARY;

ANIMALS; CITRUS PARADISI; COLONIC NEOPLASMS; GENETIC THERAPY; GENETIC VECTORS; LIPIDS; LIVER NEOPLASMS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICRORNAS; NANOPARTICLES; PLANT EXTRACTS;

EID: 84967018517     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8361     Document Type: Article

References (45)

1. Lujambio A, Akkari L, Simon J, Grace D, TschaharganehDF, Bolden JE, Zhao Z, Thapar V, Joyce JA, KrizhanovskyV, Lowe SW. Non-cell-autonomous tumor suppression by p53. Cell. 2013; 153:449-460.
2. Rushfeldt C, Sveinbjornsson B, Seljelid R, Smedsrod B. Early events of hepatic metastasis formation in mice: role of Kupffer and NK-cells in natural and interferon-gamma-stimulated defense. J Surg Res. 1999; 82:209-215.
3. Shiratori Y, Nakata R, Okano K, Komatsu Y, Shiina S, Kawase T, Sugimoto T, Omata M, Tanaka M. Inhibition of hepatic metastasis of colon carcinoma by asialo GM1-positive cells in the liver. Hepatology. 1992; 16:469-478.
4. Roh MS, Kahky MP, Oyedeji C, Klostergaard J, WangL, Curley SA, Lotzova E. Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases. Clin Exp Metastasis. 1992; 10:317-327.
5. Matsumura H, Kondo T, Ogawa K, Tamura T, Fukunaga K, Murata S, Ohkohchi N. Kupffer cells decrease metastasis of colon cancer cells to the liver in the early stage. Int J Oncol. 2014; 45:2303-2310.
6. Miyagawa S, Miwa S, Soeda J, Kobayashi A, KawasakiS. Morphometric analysis of liver macrophages in patients with colorectal liver metastasis. Clin Exp Metastasis. 2002; 19:119-125.
7. Van den Eynden GG, Majeed AW, Illemann M, VermeulenPB, Bird NC, Hoyer-Hansen G, Eefsen RL, Reynolds AR, Brodt P. The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res. 2013; 73:2031-2043.
8. Kruse J, von Bernstorff W, Evert K, Albers N, Hadlich S, Hagemann S, Gunther C, van Rooijen N, Heidecke CD, Partecke LI. Macrophages promote tumour growth and liver metastasis in an orthotopic syngeneic mouse model of colon cancer. Int J Colorectal Dis. 2013; 28:1337-1349.
9. Parker GA, Picut CA. Immune functioning in non lymphoid organs: the liver. Toxicol Pathol. 2012; 40:237-247.
10. Miyamoto M, Emoto M, Brinkmann V, van RooijenN, Schmits R, Kita E, Kaufmann SH. Cutting edge: contribution of NK cells to the homing of thymic CD4+NKT cells to the liver. J Immunol. 2000; 165:1729-1732.
11. Seki S, Nakashima H, Nakashima M, Kinoshita M. Antitumor immunity produced by the liver Kupffer cells, NK cells, NKT cells, and CD8 CD122 T cells. Clin Dev Immunol. 2011; 2011:868345.
12. Seki S, Habu Y, Kawamura T, Takeda K, Dobashi H, Ohkawa T, Hiraide H. The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev. 2000; 174:35-46.
13. Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, Chmielewski K, Stewart KM, Ashall J, Everts B, Pearce EJ, Driggers EM, Artyomov MN. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015; 42:419-430.
14. Murray PJ, Allen JE, Biswas SK, Fisher EA, GilroyDW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, LawrenceT, Locati M, Mantovani A, Martinez FO, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014; 41:14-20.
15. Xue J, Schmidt SV, Sander J, Draffehn A, KrebsW, QuesterI, De Nardo D, Gohel TD, Emde M, Schmidleithner L, GanesanH, Nino-Castro A, MallmannMR, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014; 40:274-288.
16. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, YangSM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012; 2012:948098.
17. Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG. TGF-beta-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene. 2011; 30:2475-2484.
18. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T, Takami T. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008; 83:1136-1144.
19. Bastos KR, Alvarez JM, Marinho CR, Rizzo LV, LimaMR. Macrophages from IL-12p40-deficient mice have a bias toward the M2 activation profile. J Leukoc Biol. 2002; 71:271-278.
20. Ryan AE, Colleran A, O'Gorman A, O'Flynn L, Pindjacova J, Lohan P, O'Malley G, Nosov M, Mureau C, Egan LJ. Targeting colon cancer cell NF-kappaB promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis. Oncogene. 2015; 34:1563-1574.
21. Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2013; 62:1757-1768.
22. Costa NL, Valadares MC, Souza PP, Mendonca EF, Oliveira JC, Silva TA, Batista AC. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol. 2013; 49:216-223.
23. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, van Hall T, van der Burg SH. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011; 187:1157-1165.
24. Duluc D, Corvaisier M, Blanchard S, Catala L, DescampsP, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009; 125:367-373.
25. Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 2015; 8:re3.
26. Yang F, Zhang W, Shen Y, Guan X. Identification of dysregulated microRNAs in triple-negative breast cancer (review). Int J Oncol. 2015; 46:927-932.
27. Joshi P, Middleton J, Jeon YJ, Garofalo M. MicroRNAs in lung cancer. World J Methodol. 2014; 4:59-72.
28. Oom AL, Humphries BA, Yang C. MicroRNAs: novel players in cancer diagnosis and therapies. Biomed Res Int. 2014; 2014:959461.
29. Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets. 2012; 16:747-759.
30. Parasramka MA, Ho E, Williams DE, Dashwood RH. MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals. Mol Carcinog. 2012; 51:213-230.
31. Wang Z, Brandt S, Medeiros A, Wang S, Wu H, Dent A, Serezani CH. MicroRNA 21 is a homeostatic regulator of macrophage polarization and prevents prostaglandin E2-mediated M2 generation. PLoS One. 2015; 10:e0115855.
32. Caescu CI, Guo X, Tesfa L, Bhagat TD, Verma A, ZhengD, Stanley ER. Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21. Blood. 2015; 125:e1-13.
33. Xu S, Wei J, Wang F, Kong LY, Ling XY, Nduom E, Gabrusiewicz K, Doucette T, Yang Y, Yaghi NK, Fajt V, Levine JM, Qiao W, et al. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst. 2014; 106.
34. Veremeyko T, Siddiqui S, Sotnikov I, Yung A, Ponomarev ED. IL-4/IL-13-dependent and independent expression of miR-124 and its contribution to M2 phenotype of monocytic cells in normal conditions and during allergic inflammation. PLoS One. 2013; 8:e81774.
35. Zhou D, Huang C, Lin Z, Zhan S, Kong L, Fang C, Li J. Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell Signal. 2014; 26:192-197.
36. Moore CS, Rao VT, Durafourt BA, Bedell BJ, Ludwin SK, Bar-Or A, Antel JP. miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol. 2013; 74:709-720.
37. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013; 14:996-1006.
38. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014; 14:181-194.
39. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006; 26:1175-1186.
40. Wang Q, Ren Y, Mu J, Egilmez NK, Zhuang X, Deng Z, Zhang L, Yan J, Miller D, Zhang HG. Grapefruit-derived nanovectors use an activated leukocyte trafficking pathway to deliver therapeutic agents to inflammatory tumor sites. Cancer Res. 2015; 75:2520-9. doi: 10.1158/0008-5472.CAN-14-3095.
41. Wang Q, Zhuang X, Mu J, Deng ZB, Jiang H, Zhang L, Xiang X, Wang B, Yan J, Miller D, Zhang HG. Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. Nat Commun. 2013; 4:1867.
42. Humphreys KJ, McKinnon RA, Michael MZ. miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells. PLoS One. 2014; 9:e112288.
43. Jiang H, Wang P, Wang Q, Wang B, Mu J, Zhuang X, Zhang L, Yan J, Miller D, Zhang HG. Quantitatively controlling expression of miR-17~92 determines colon tumor progression in a mouse tumor model. Am J Pathol. 2014; 184:1355-1368.
44. Leonard JP, Sherman ML, Fisher GL, BuchananLJ, LarsenG, Atkins MB, Sosman JA, DutcherJP, VogelzangNJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997; 90:2541-2548.
45. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology. 2009; 136:683-693.